US 9,416,157 · Application 13/360,163 · Granted Aug 16, 2016
US 9,416,157
Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity
Estimated expiration
December 11, 2026
75 days remaining
- Could not fetch continuity data for application PCTCA2006001650: Resource not found (404)
Earliest effective filing
Oct 4, 2006
+ 20 years
Oct 4, 2026
PTA +906d
Mar 28, 2029
TD cap (US 8,791,061)
Dec 11, 2026
Final
Dec 11, 2026
This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included. Terminal disclaimers can affect PTA (In re Cellect, LLC).
Calculation details
Base term
- Filing date
- January 27, 2012
- Earliest effective filing
- October 4, 2006
- Issue date
- August 16, 2016
- PTA
- +906 days
- Base expiry (before PTA)
- October 4, 2026
October 4, 2006 + 20 years = October 4, 2026 + 906 PTA days = March 28, 2029
- Continuation of application 12/083,086, filed Apr 4, 2008, issued as US 8,124,721
- National stage entry of application PCTCA2006001650, filed Oct 4, 2006
- National stage entry of application PCTCA2006001650, filed Oct 4, 2006
- PRO60/722,962 — Provisional — not used for base term
- PRO60/722,958 — Provisional — not used for base term
- PRO60/722,959 — Provisional — not used for base term
- PRO60/722,962 — Provisional — not used for base term
- PRO60/722,958 — Provisional — not used for base term
- PRO60/722,959 — Provisional — not used for base term
Terminal disclaimers
TD caps expiration to December 11, 2026 (earliest expiring referenced patent: US 8,791,061)
US 8,124,721· Application 12/083,086Capping patent
Peptides for modulating innate immunity
- Filing date
- Apr 4, 2008
- Earliest effective filing
- Oct 4, 2006
- Issue date
- Feb 28, 2012
- PTA
- +546 days
- Calculated expiration
- Apr 2, 2028
National stage entry of PCTCA2006001650, filed Oct 4, 2006
Oct 4, 2006 + 20y + 546d PTA = Apr 2, 2028
US 9,416,157· Application 13/360,163(from application 13/360,163)
Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity
- Filing date
- Jan 27, 2012
- Earliest effective filing
- Oct 4, 2006
- Issue date
- Aug 16, 2016
- PTA
- +906 days
- Calculated expiration
- Mar 28, 2029
Continuation of 12/083,086, filed Apr 4, 2008, issued as US 8,124,721
National stage entry of PCTCA2006001650, filed Oct 4, 2006
National stage entry of PCTCA2006001650, filed Oct 4, 2006
Oct 4, 2006 + 20y + 906d PTA = Mar 28, 2029
US 8,791,061· Application 13/457,162Capping patent
Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity
- Filing date
- Apr 26, 2012
- Earliest effective filing
- Oct 4, 2006
- Issue date
- Jul 29, 2014
- PTA
- +68 days
- Calculated expiration
- Dec 11, 2026
Continuation of 12/404,965, filed Mar 16, 2009
Continuation of 11/730,695, filed Apr 3, 2007
Continuation of 11/730,695, filed Apr 3, 2007
Continuation-in-part of 13/360,163, filed Jan 27, 2012, issued as US 9,416,157
Continuation of 12/083,086, filed Apr 4, 2008, issued as US 8,124,721
National stage entry of PCTCA2006001650, filed Oct 4, 2006
National stage entry of PCTCA2006001650, filed Oct 4, 2006
Continuation of 12/083,086, filed Apr 4, 2008, issued as US 8,124,721
National stage entry of PCTCA2006001650, filed Oct 4, 2006
Oct 4, 2006 + 20y + 68d PTA = Dec 11, 2026
US 8,791,061· Application 13/457,162(from application 13/457,162)
Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity
- Filing date
- Apr 26, 2012
- Earliest effective filing
- Oct 4, 2006
- Issue date
- Jul 29, 2014
- PTA
- +68 days
- Calculated expiration
- Dec 11, 2026
Continuation of 12/404,965, filed Mar 16, 2009
Continuation of 11/730,695, filed Apr 3, 2007
Continuation of 11/730,695, filed Apr 3, 2007
Continuation-in-part of 13/360,163, filed Jan 27, 2012, issued as US 9,416,157
Continuation of 12/083,086, filed Apr 4, 2008, issued as US 8,124,721
National stage entry of PCTCA2006001650, filed Oct 4, 2006
National stage entry of PCTCA2006001650, filed Oct 4, 2006
Continuation of 12/083,086, filed Apr 4, 2008, issued as US 8,124,721
National stage entry of PCTCA2006001650, filed Oct 4, 2006
Oct 4, 2006 + 20y + 68d PTA = Dec 11, 2026
Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated
The prosecution record for your AI
Application 13/360,163 · US 9,416,157
You have the date. Your AI can have the file.
PatentReply compiles the prosecution history behind US 9,416,157: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.
One public application a month is free. The first compile takes a few minutes.
Strategy and filing changes require your approval.
Permanent link
www.patentreply.ai/tools/patent-expiration/US9416157Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.